The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Evaluating Financial Incentives as a Tool to Increase Medication Adherence for Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Education-based and behaviour change interventions improve patient knowledge regarding statin therapy and CVD risk assessment and change their behaviours through regular reminders and monitoring.[86][87][88]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hong, Q. N., Gonzalez‐Reyes, A., & Pluye, P. (2018) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12884 · Cited by 1,107 · cited 1×
“We used the Mixed Methods Appraisal Tool to assess the risk of methodological bias, as we included different study types [13].”
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979 · cited 1×
“…despite the availability of prescription drugs proven to regulate blood glucose levels and decrease the risk of complications, it is estimated that anywhere from 30 to 90% of people living with T2DM (PLWD) are not reaching their glycemic goals owing to non-adherence to medication treatments [3, 4].”
Viswanathan, M., Golin, C. E., Jones, C. D., Ashok, M., Blalock, S. J., Wines, R. C. M., Coker-Schwimmer, E. J. L., Rosen, D. L., Sista, P., & Lohr, K. N. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-11-201212040-00538 · Cited by 754 · cited 1×
“Other reviews and studies assessing types of financial incentives such as cost-sharing and value-based insurance also demonstrate small but positive increases in adherence to medicines for chronic conditions [44, 45].”
A systematic overview of systematic reviews evaluating medication adherence interventions
Anderson, L. J., Nuckols, T. K., Coles, C., Le, M. M., Schnipper, J. L., Shane, R., Jackevicius, C., Lee, J., Pevnick, J. M., Members of the PHARM-DC Group, et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz284 · Cited by 122 · cited 2×
“For example, a review of reviews revealed that two out of three had positive results and that financial incentives increased medication adherence in patients with chronic diseases [10].”
Cost-related medication non-adherence among U.S. adults with diabetes
Kang, H., Lobo, J. M., Kim, S., & Sohn, M.-W. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.016 · Cited by 119
Research and scholarly methods: Measuring medication adherence
Shah, K. K., Touchette, D. R., & Marrs, J. C. (2023) · JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1771 · Cited by 69 · cited 1×
“Other studies have shown that MPR tends to be biased upward, which may contribute to the effect [58].”
Burton, A., Marougka, S., & Priebe, S. (2010) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00001160 · Cited by 30
Research works printed but not linked: 50
- Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88(11):1322–35. · DOI · Paper page
- Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, et al. Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20(1 Suppl):s5-15.
- Morris JL, Chasens ER. Financial difficulty: a barrier to self-care in patients with diabetes. Diabetes Educ. 2017;43(3):247–8. · doi:10.1177/0145721717703486
- Doshi JA, Li P, Ladage VP, Pettit AR, Taylor EA. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions. Am J Manag Care. 2016;22(3):188–97.
- Choe HM, Stevenson JG, Streetman DS, Heisler M, Sandiford CJ, Piette JD. Impact of patient financial incentives on participation and outcomes in a statin pill-splitting program. Am J Manag Care. 2007;13(6 Part 1):298–304.
- Jackson T, Shields MD, Heaney LG, Kendall M, Pearce CJ, Hui CY, et al. The impact of financial incentives on the implementation of asthma or diabetes self-management: a systematic review. PLoS ONE. 2017;12(11): e0187478. · DOI
- Fusco N, Sils B, Graff JS, Kistler K, Ruiz K. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: a systematic literature review. J Manag Care Spec Pharm 2022; https://doi.org/10.18553/jmcp.2022.21270 · DOI
- Sensharma A, Yabroff KR. Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies. Expert Rev Pharmacoecon Outcomes Res. 2019;19(3):263–77. · DOI
- Ihle P, Krueger K, Schubert I, Griese-Mammen N, Parrau N, Laufs U, et al. Comparison of different strategies to measure medication adherence via claims data in patients with chronic heart failure. Clin Pharmacol Ther. 2019;106(1):211–8. · DOI
- Weir CJ, Butcher I, Assi V, Lewis SC, Murray GD, Langhorne P, et al. Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review. BMC Med Res Methodol. 2018;18(1):25. · DOI · Paper page
- Reis DJ, Kaizer AM, Kinney AR, et al. A practical guide to random-effects Bayesian meta-analyses with application to the psychological trauma and suicide literature. Psychol Trauma. 2023;15(1):121. · DOI
- Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7.
- Hohmann NS, Hastings TJ, Jeminiwa RN, Qian J, Hansen RA, Ngorsuraches S, et al. Patient preferences for medication adherence financial incentive structures: a discrete choice experiment. Res Social Adm Pharm. 2021;17(10):1800–9. · DOI
- Bilger M, Shah M, Tan NC, Tan CYL, Bundoc FG, Bairavi J, et al. Process- and outcome-based financial incentives to improve self-management and glycemic control in people with Type 2 diabetes in Singapore: a randomized controlled trial. Patient. 2021;14(5):555–67. · DOI
- Chang A, Liberman JN, Coulen C, Berger JE, Brennan TA. Value-based insurance design and antidiabetic medication adherence. Am J Pharm Benefits. 2010;2(1):39–44.
- Clark B, DuChane J, Hou J, Rubinstein E, McMurray J, Duncan I. Evaluation of increased adherence and cost savings of an employer value-based benefits program targeting generic antihyperlipidemic and antidiabetic medications. J Manag Care Pharm. 2014;20(2):141–50.
- Gibson TB, Wang S, Kelly E, Brown C, Turner C, Frech-Tamas F, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood). 2011;30(1):109–17. · DOI
- Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Value-based insurance plus disease management increased medication use and produced savings. Health Aff (Millwood). 2011;30(1):100–8. · DOI
- Gibson TB, Mahoney JJ, Lucas K, Heithoff K, Gatwood J. Value-based design and prescription drug utilization patterns among diabetes patients. Am J Pharm Benefits. 2013;5(3):113–20.
- Gokhale M, Dusetzina SB, Pate V, Chun DS, Buse JB, Stürmer T, et al. Decreased antihyperglycemic drug use driven by high out-of-pocket costs despite medicare coverage gap closure. Diabetes Care. 2020;43(9):2121–7. · DOI
- Kim NH, Look KA. The effect of reduced drug copayments on adherence to oral diabetes medications among childless adults in Wisconsin Medicaid. J Manag Care Spec Pharm. 2019;25(12):1432–41.
- Kong E, Beshears J, Laibson D, Madrian B, Volpp K, Loewenstein G, et al. Do physician incentives increase patient medication adherence? Health Serv Res. 2020;55(4):503–11. · DOI
- Karter AJ, Parker MM, Solomon MD, Lyles CR, Adams AS, Moffet HH, et al. Effect of out-of-pocket cost on medication initiation, adherence, and persistence among patients with Type 2 diabetes: The Diabetes Study of Northern California (DISTANCE). Health Serv Res. 2018;53(2):1227–47. · DOI
- Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002–8. · DOI
- Musich S, Wang S, Hawkins K. The impact of a value-based insurance design plus health coaching on medication adherence and medical spending. Popul Health Manag. 2015;18(3):151–8. · DOI
- Peaslee A, Wickizer M, Olson J, Topp R. Impact of a combined value-based insurance design and medication therapy management program on diabetes medication adherence. J Manag Care Spec Pharm. 2016;22(11):1303–9.
- Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S. Changes in drug utilization during a gap in insurance coverage: An examination of the medicare part d coverage gap. PLoS Medicine. 2011;8(8): e1001075. · DOI
- Pooler JA, Srinivasan M. Association between supplemental nutrition assistance program participation and cost-related medication non-adherence among older adults with diabetes. JAMA Intern Med. 2019;179(1):63–70. · DOI
- Rastas C, Bunker D, Gampa V, Gaudet J, Karimi S, Majidi A, et al. Association between high deductible health plans and cost-related non-adherence to medications among americans with diabetes: an observational study. J Gen Intern Med. 2021;37:1910–6. · DOI
- Reiss SK, Ross-Degnan D, Zhang F, Soumerai SB, Zaslavsky AM, Wharam JF. Effect of switching to a high-deductible health plan on use of chronic medications. Health Serv Res. 2011;46(5):1382–401. · DOI
- Roblin DW, Platt R, Goodman MJ, Hsu J, Nelson WW, Smith DH, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: How much is too much? Med Care. 2005;43(10):951–9. · DOI
- Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, et al. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015;21(4):269–75.
- Wang V, Liu CF, Bryson CL, Sharp ND, Maciejewski ML. Does medication adherence following a copayment increase differ by disease burden? Health Serv Res. 2011;46(6):1963–85. · DOI
- Wong ES, Maciejewski ML, Liu CF. Does the association between prescription copayment increases and medication adherence differ by race? J Health Care Poor Underserved. 2013;24(3):1317–30. · DOI
- Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13(6):846–52. · DOI
- Latham LP, Marshall EG. Performance-based financial incentives for diabetes care: an effective strategy? Can J Diabetes. 2015;39(1):83–7. · DOI
- Hung A, Blalock DV, Miller J, McDermott J, Wessler H, Oakes MM, et al. Impact of financial medication assistance on medication adherence: a systematic review. J Manag Care Spec Pharm. 2021;27(7):924–35.
- DeFulio A, Silverman K. The use of incentives to reinforce medication adherence. Prev Med. 2012;55(Suppl):S86-94. · DOI
- Jeminiwa R, Hohmann SN, Hastings JT, Hansen R, Qian J, Garza BK. Individuals’ preference for financial over social incentives for medication adherence. J Am Pharm Assoc. 2022;62(1):134-41.e1. · DOI
- Noordraven LE, Schermer NHM, Blanken P, Mulder LC, Wierdsma IA. Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients’ and clinicians’ perspectives after a 12-month randomized controlled trial. BMC Psychiatry. 2017. https://doi.org/10.1186/s12888-017-1485-x. · DOI
- Vlaev I, King D, Darzi A, Dolan P. Changing health behaviors using financial incentives: a review from behavioral economics. BMC Public Health. 2019. https://doi.org/10.1186/s12889-019-7407-8. · DOI · Paper page
- Priebe S, Yeeles K, Bremner S, Lauber C, Eldridge S, Ashby D, et al. Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial. BMJ. 2013;347(7oct07 3):f5847. https://doi.org/10.1136/bmj.f5847. · DOI
- Nichols GA, Rosales AG, Kimes TM, Tunceli K, Kurtyka K, Mavros P. The change in HbA1c associated with initial adherence and subsequent change in adherence among diabetes patients newly initiating metformin therapy. J Diabetes Res. 2016;2016:9687815. · DOI
- Mata-Cases M, Rodríguez-Sánchez B, Mauricio D, Real J, Vlacho B, Franch-Nadal J, et al. The association between poor glycemic control and health care costs in people with diabetes: a population-based Study. Diabetes Care. 2020;43(4):751–8. · DOI
- Barankay I, Reese PP, Putt ME, Russell LB, Loewenstein G, Pagnotti D, et al. Effect of patient financial incentives on statin adherence and lipid control: a randomized clinical trial. JAMA Netw Open. 2020;3(10): e2019429. · DOI · Paper page
- Nally ML, Wagner J, Sherr J, Tichy E, Weyman K, Ginley KM, et al. A pilot study of youth with Type 1 diabetes initiating use of a hybrid closed-loop system while receiving a behavioral economics intervention. Endocr Pract. 2021;27(6):545–51. · DOI
- Gross CA, Freese LR, Bensignor OM, Bomberg ME, Dengel RD, Fox KC, et al. Financial incentives and treatment outcomes in adolescents with severe obesity. JAMA Pediatr. 2024;178(8):753. · DOI
- Desai JR, Vazquez-Benitez G, Taylor G, Johnson S, Anderson J, Garrett JE, et al. The effects of financial incentives on diabetes prevention program attendance and weight loss among low-income patients: the we can prevent diabetes cluster-randomized controlled trial. BMC Public Health. 2020;20(1):1587. · DOI
- Noordraven EL, Wierdsma AI, Blanken P, Bloemendaal AFT, Mulder CL. Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial. BMC Res Notes. 2018;11(1):655. · doi:10.1186/s13104-018-3747-1
- Henderson C, Knapp M, Yeeles K, Bremner S, Eldridge S, David AS, et al. Cost-effectiveness of financial incentives to promote adherence to depot antipsychotic medication: economic evaluation of a cluster-randomised controlled trial. PLoS One. 2015;10(10): e0138816. · DOI
Cited by
Rakhshanda, S., Briggs, N. E., Rhee, J., Rye, K.-A., Liaw, S.-T., & Jonnagaddala, J. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag175 · Cited by 6
Metadata
- Authors
- Winberg, D., Tang, T., Ramsey, Z., Bazzano, A. N., Nauman, E., Li, J., Lin, Y., & Shi, L.
- Venue
- Diabetes Therapy
- Published
- 2025-02-10
- ISSN
- 1869-6953
- 1869-6961
- Cited by
- 3
- References
- 7
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Funders
- Centers for Disease Control and Prevention (1U18DP006523-01)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating Financial Incentives as a Tool to Increase Medication Adherence for Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1007/s13300-025-01694-y
- The paper
- Winberg, D., Tang, T., Ramsey, Z., Bazzano, A. N., Nauman, E., Li, J., Lin, Y., & Shi, L. (2025). Evaluating Financial Incentives as a Tool to Increase Medication Adherence for Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-025-01694-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.